NT-1535

N/A

Report date: 2025/01/26 16:23:36

Base Information

Drug NameNT-1535

Drug Alias Nameanti-TP53/KRAS/neoantigen TCR T-cell therapy (NCI/Neogene Therapeutics)NT-1535

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyBiologics > Protein drugs > Recombinant protein

Mechanisms of ActionTumor protein p53 modulatorsHuman leukocyte antigen modulators

TargetsTumor protein p53Human leukocyte antigen

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesNetherlands

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesNational Cancer Institute

China Registration ClassN/A

Develop Information

Active CompaniesNeogene Therapeutics Inc

Inactive CompaniesNational Cancer Institute

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A